Meds & supplements › Asciminib
Medicine
SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
SCEMBLIX is indicated for the treatment of adult patients with:
The following clinically significant adverse reactions can occur with SCEMBLIX and are discussed in greater detail in other sections of the labeling:
None.
sofidex [Internet]. Daloreum; c2026. Asciminib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/asciminib
sofidex. (2026, August 2). Asciminib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/asciminib
Asciminib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/asciminib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.